ATR241115P155000
- 9.40
- 0.000.00%
AptarGroup Newsroom
DBS Upgrades AptarGroup(ATR.US) to Buy Rating, Raises Target Price to $200
AptarGroup Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $185
Wells Fargo Sticks to Their Buy Rating for AptarGroup (ATR)
AptarGroup Analyst Ratings
Jefferies Initiates AptarGroup(ATR.US) With Buy Rating, Announces Target Price $215
Baird Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $170
BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $174
AptarGroup: Hold Rating Justified by Solid Pharma Performance Amidst Growth and Margin Challenges
Baird Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $170
Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), AptarGroup (ATR) and AbbVie (ABBV)
BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $168
Bank of America Securities Sticks to Their Buy Rating for AptarGroup (ATR)
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR) and Aura Biosciences Inc (AURA)
AptarGroup Analyst Ratings
BofA Securities Adjusts Price Target on AptarGroup to $163 From $160
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)
Wells Fargo Maintains Overweight on AptarGroup, Raises Price Target to $163
Baird: The AptarGroup (ATR.US) rating was maintained, and the target price was adjusted from better than the market to the better than the market rating, and the target price was adjusted from $150.00 to $170.00.
AptarGroup Analyst Ratings